Janssen becomes the third assay content provider for Biocartis' integrated "sample-to-answer" nucleic acid testing platform as the company drives toward a full commercial launch in the second half of 2012.
Janssen and J&J's Ortho-Clinical Diagnostics group have worldwide exclusive rights to develop and commercialize assays on the Biocartis platform in the fields of neurological disease and certain viral infectious diseases.
Debiopharm, which participated in the financing round as a new investor, announced separately that it will be collaborating with Biocartis to develop companion diagnostics for therapies in the areas of oncology and infectious disease.
The Swiss firm said that it will use the cash to accelerate development and validation of the first version of its forthcoming molecular diagnostics platform, which will incorporate nucleic acid sample prep technology recently acquired from Royal Philips Electronics.
The platform features new nucleic acid sample prep and amplification technologies and will be developed for a wide range of DNA and RNA molecular diagnostic testing, including in oncology and infectious diseases, according to a Biocartis executive.